Suresh Vittal
In January 2021, we entered into an offer letter with Suresh Vittal, our Chief Product Officer. The offer letter has no specific term and provides for at-will employment. See “Executive Compensation—Compensation Discussion and Analysis—Elements of Compensation” for Mr. Vittal’s base salary, target bonus and equity awards during 2022.
For information regarding payments made to Mr. Vittal for the year ended December 31, 2022, see the “Summary Compensation Table” above.
Christopher Lal
In March 2017, we entered into an amended and restated offer letter with Christopher M. Lal, our Chief Legal Officer and Corporate Secretary. The offer letter has no specific term and provides for at-will employment. See “Executive Compensation—Compensation Discussion and Analysis—Elements of Compensation” for Mr. Lal’s base salary, target bonus and equity awards during 2022.
For information regarding payments made to Mr. Lal for the year ended December 31, 2022, see the “Summary Compensation Table” above.
Potential Payments upon Termination or Change in Control
Named Executive Officer Severance and Change in Control Agreements
We have entered into severance and change in control agreements, or Severance and Change in Control Agreements, with each of our named executive officers. These agreements provide for each named executive officer to receive the benefits described below upon either a termination by us of the executive officer’s employment without “cause” or a voluntary resignation by the executive officer from his or her employment with “good reason” (each as defined in the Severance and Change in Control Agreement). We refer to either of these terminations as a “qualifying termination.” These benefits are contingent upon the executive officer executing a customary release of claims.
The benefits provided under the Severance and Change in Control Agreements vary depending on whether the executive officer is subject to the qualifying termination within a period beginning three months before a change in control (as defined in the Severance and Change in Control Agreement) and ending 12 months after a change in control, or the “change in control period.”
If a qualifying termination occurs prior to or after the change in control period, each of Messrs. Anderson, Rubin, Vittal and Lal and Ms. Hansen will be entitled to: (i) 12 months’, nine months’, nine months’, nine months’, and nine months’ of continued payment of base salary, respectively, and (ii) if the executive officer elects to continue his or her health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, then payment of the premiums for his or her continued health insurance (or equivalent cash payment, if applicable law so requires) for up to 12 months, nine months, nine months, nine months and nine months, respectively.
If a qualifying termination occurs during the change in control period, each of Messrs. Anderson, Rubin, Vittal, and Lal and Ms. Hansen will be entitled to: (i) 18 months’, 12 months’, 12 months’, 12 months’, and 12 months’ of continued payment of base salary, respectively, (ii) if the executive officer elects to continue his or her health insurance coverage under COBRA, then payment of the premiums for his or her continued health insurance (or equivalent cash payment, if applicable law so requires) for up to 18 months, 12 months, 12 months, 12 months, and 12 months, respectively, (iii) full acceleration of each of the executive officer’s then-outstanding but unvested equity awards, except that awards subject to the satisfaction of performance criteria would accelerate if, and only to the extent, set forth in the applicable award agreement, and (iv) 100% of his or her annual target bonus opportunity at the rate in effect when the qualifying termination occurred or when the change in control occurred, whichever is greater. These benefits and acceleration are contingent upon the consummation of the change in control.
If a change in control occurred and our successor or acquirer refused to assume, convert, replace or substitute the then-outstanding and unvested equity awards held by the eligible named executive officers, then those awards would accelerate in full, except that awards subject to the satisfaction of performance criteria would accelerate if, and only to the extent, set forth in the applicable award agreement.